InspireMD (NYSE:NSPR) Stock Price Up 3.5% – Time to Buy?

Shares of InspireMD, Inc. (NYSE:NSPR) rose 3.5% during trading on Thursday . The stock traded as high as $1.2399 and last traded at $1.18. Approximately 69,700 shares traded hands during mid-day trading, an increase of 73% from the average daily volume of 40,388 shares. The stock had previously closed at $1.14.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NSPR shares. Lake Street Capital restated a “buy” rating on shares of InspireMD in a report on Tuesday, February 24th. Maxim Group started coverage on shares of InspireMD in a report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective for the company. Finally, Loop Capital set a $5.00 target price on shares of InspireMD in a research report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, InspireMD currently has a consensus rating of “Buy” and an average price target of $5.00.

InspireMD Stock Down 2.5%

The business has a 50-day simple moving average of $1.55 and a 200-day simple moving average of $1.78. The stock has a market cap of $53.93 million, a P/E ratio of -1.53 and a beta of 0.95.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NSPR. XTX Topco Ltd bought a new position in InspireMD in the 4th quarter worth $30,000. Virtu Financial LLC bought a new stake in InspireMD during the fourth quarter valued at about $31,000. Creative Planning acquired a new stake in shares of InspireMD in the second quarter valued at about $44,000. Legato Capital Management LLC bought a new position in shares of InspireMD in the fourth quarter worth about $48,000. Finally, Uniting Wealth Partners LLC bought a new position in shares of InspireMD in the third quarter worth about $51,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.